Modafinil and the related agent armodafinil are FDA-approved for narcolepsy, OSA-residual excessive daytime sleepiness, and shift work disorder. The mechanism — dopamine transporter inhibition, histaminergic activation, orexin pathway support — produces wakefulness with substantially less CNS activation than stimulant medications, lower abuse potential, and a different side-effect profile. The clinical footprint extends beyond approved indications into off-label use for cognitive complaints in depression, ADHD-spectrum conditions, fatigue in multiple sclerosis and other neurological conditions, and broader cognitive enhancement scenarios.
The approved indications. Narcolepsy — modafinil 200mg in the morning, armodafinil 150mg, with established efficacy and tolerability. OSA-residual sleepiness — added to CPAP when persistent sleepiness remains despite adequate CPAP adherence. Shift work disorder — taken 1 hour before shift start. Each indication is supported by trial evidence and reflects the agent's specific wakefulness-promoting profile.
Off-label use in cognitive complaints of depression. Patients with depression and prominent fatigue, hypersomnia, or cognitive complaints may benefit from modafinil augmentation. Evidence is suggestive but limited; case-level use is common in residency-edge psychiatric practice. Effect sizes appear modest but the side-effect profile is favorable for selected patients. Insurance coverage typically requires approved indication; off-label use frequently requires patient self-pay or specific prior authorization.
Off-label use in ADHD-spectrum conditions. Modafinil has shown some evidence in adult ADHD, particularly in patients with stimulant intolerance or contraindications. Effect sizes smaller than stimulants but not negligible. Not FDA-approved for ADHD; the clinical use is selective. The Cephalon trials in childhood ADHD did not lead to FDA approval (rare serious dermatologic adverse events) but adult use considerations are different.
The cognitive enhancement and longevity-psychiatry considerations. Modafinil is widely used off-label for cognitive enhancement in healthy adults — students, professionals, others. The evidence in healthy populations shows modest improvement in some cognitive domains (working memory, attention, particularly in sleep-deprived states) with less effect in well-rested individuals. The ethical and clinical considerations include: long-term safety data is more limited than for stimulants; the marginal benefit in non-pathological populations is small; psychological dependence is possible. The longevity-psychiatry frame engages modafinil where it addresses specific clinical needs (sleep disorder residual symptoms, depression cognitive symptoms, neurological fatigue) rather than as general cognitive enhancement. The discipline is to use modafinil for indications where it has clear clinical place, prescribe specifically with realistic expectations, and avoid the casual off-label use that does not serve patient interests.